PYC Therapeutics, a developer of RNA therapies for genetic diseases and capitalised at $933 million on the ASX, confirmed a $653 million equity raising on Monday morning after Street Talk revealed the ...

Game decompilations have been in the news on and off again for quite some time. It’s the act of reverse engineering games to run natively on PC (or any hardware, in theory). Now, there’s potential for ...

Abstract: Python is one of the most popular programming languages among both industry developers and malware authors. Despite demand for Python decompilers, community efforts to maintain automatic ...

A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. The group holding the most number of shares in the company, around 45% to be precise, is ...

The S&P/ASX 200 Index is falling on Wednesday, with Flight Centre, Inghams, New Hope Corporation, and PYC Therapeutics shares declining significantly. Both Flight Centre and Inghams' share prices ...

PYC Therapeutics has built a pipeline of drug candidates addressing rare genetic diseases, with three assets now in clinical stages. The company’s strategy centers on using RNA therapeutics to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The dosing of patients with polycystic kidney disease is set to begin this month. Credit: SewCreamStudio / Shutterstock. PYC Therapeutics is set to begin Part B in its single ascending dose (SAD) ...

Community driven content discussing all aspects of software development from DevOps to design patterns. When you install Java, the JDK comes with a number of helpful utilities packed within the ...

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters. Clinical-stage biotechnology company PYC ...